サンプル依頼リスト カート
  • English
  • Korean
デフォルト表紙
市場調査レポート
商品コード
1513896

注意欠陥多動性障害（ADHD）治療薬の世界市場

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics

出版日
ページ情報
英文 186 Pages
納期
即日から翌営業日
適宜更新あり
価格
価格表記: USDを日本円(税抜)に換算
本日の銀行送金レート: 1USD=146.99円
注意欠陥多動性障害（ADHD）治療薬の世界市場
出版日: 2024年07月17日
発行: Global Industry Analysts, Inc.
ページ情報: 英文 186 Pages
納期: 即日から翌営業日
GIIご利用のメリット
  • 全表示
  • 概要
  • 目次
概要

注意欠陥多動性障害（ADHD）治療薬の世界市場は2030年までに577億米ドルに達する見込み

2023年に346億米ドルと推定される注意欠陥多動性障害（ADHD）治療薬の世界市場は、分析期間2023-2030年にCAGR 7.6%で成長し、2030年には577億米ドルに達すると予測されます。本レポートで分析したセグメントの1つである覚せい剤は、CAGR 7.1%を記録し、分析期間終了時には477億米ドルに達すると予測されます。非刺激剤セグメントの成長率は、分析期間中CAGR 10.1%と推定されます。

米国市場は92億米ドル、中国はCAGR 7.1％で成長すると予測

米国の注意欠陥多動性障害（ADHD）治療薬市場は2023年に92億米ドルと推定されます。世界第2位の経済大国である中国は、2030年までに90億米ドルの市場規模に達すると予測され、分析期間2023-2030年のCAGRは7.1%です。その他の注目すべき地域別市場としては、日本とカナダがあり、分析期間中のCAGRはそれぞれ6.7%と6.3%と予測されています。欧州では、ドイツがCAGR 5.9%で成長すると予測されています。

注意欠陥多動性障害（ADHD）治療薬-主要動向と促進要因

注意欠陥多動性障害（ADHD）は、機能や発達を妨げる不注意、多動性、衝動性の持続的パターンを特徴とする神経発達障害です。ADHDは通常、小児期に発症し、成人期まで続くことがあり、学業成績、仕事、社会的交流など、生活のさまざまな側面に影響を及ぼします。本疾患は一般的に行動症状に基づいて診断され、治療には行動療法、教育的介入、薬理学的治療が組み合わされることが多いです。薬物療法はADHD管理の要であり、症状の大幅な緩和をもたらします。これらの治療は、刺激薬と非刺激薬に大別されます。メチルフェニデートやアンフェタミンなどの刺激薬は最もよく処方され、注意力を高め、多動や衝動的な行動を減らす効果があることで知られています。アトモキセチンや特定の抗うつ薬などの非刺激薬は、刺激薬に反応しない患者や副作用を経験する患者に代替薬を提供します。

ADHD治療薬市場は、この疾患に対する理解の深まりと薬理学の進歩により、過去数十年の間に大きく発展してきました。徐放性製剤の開発はADHD治療に革命をもたらし、1日1回の服用で服薬アドヒアランスを改善し、1日中一貫した症状コントロールを可能にしました。さらに、新しい非刺激薬のイントロダクションは治療の選択肢を広げ、多様なニーズや嗜好を持つ患者に対応しています。製薬会社は、ADHDに関与するさまざまな経路を標的とする新規治療薬を開発する研究に積極的に取り組んでいます。これには、現在の薬で伝統的に標的とされているドーパミンやノルエピネフリン以外の神経伝達物質の役割を探ることも含まれます。さらに、効果を最適化し副作用を最小限に抑えるために、遺伝的、環境的、ライフスタイル的要因に基づいて治療を調整することを目的とした個別化医療アプローチへの関心が高まっています。

ADHD治療薬市場の成長は、いくつかの要因によってもたらされます。診断技術の進歩やADHDに関する認知度の向上は、診断率の上昇につながり、それによって患者層の拡大につながっています。特に成人におけるADHDの有病率の上昇も、市場の成長に寄与しています。徐放性製剤や経皮パッチなどのドラッグデリバリーシステムの技術的進歩は、患者のアドヒアランスと満足度を高めています。さらに、デジタル治療薬や遠隔医療プラットフォームの開発により、特に遠隔地や医療が行き届いていない地域におけるADHD治療へのアクセスが向上しています。メンタルヘルス問題の受容が進み、ADHDに関連する偏見が減少したことで、より多くの人々が治療を受けるようになっています。さらに、新たな薬理学的標的の発見と既存の治療法の改善を目指した研究開発の継続的な取り組みが、市場を前進させると期待されています。製薬会社はまた、治療の利点についての認識を高め、早期診断と早期介入を促すために、マーケティングや教育キャンペーンに投資しています。これらの要因が総合的に、ADHD治療薬市場の堅調な成長と継続的な進化を確実なものにしています。

調査対象企業の例（注目の27社）

  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.

目次

第1章 調査手法

第2章 エグゼクティブサマリー

  • 市場概要
  • 主要企業
  • 市場動向と促進要因
  • 世界市場の見通し

第3章 市場分析

  • 米国
  • カナダ
  • 日本
  • 中国
  • 欧州
  • フランス
  • ドイツ
  • イタリア
  • 英国
  • その他欧州
  • アジア太平洋
  • 世界のその他の地域

第4章 競合

目次
Product Code: MCP-6195

Global Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market to Reach US$57.7 Billion by 2030

The global market for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics estimated at US$34.6 Billion in the year 2023, is expected to reach US$57.7 Billion by 2030, growing at a CAGR of 7.6% over the analysis period 2023-2030. Stimulant Drugs, one of the segments analyzed in the report, is expected to record a 7.1% CAGR and reach US$47.7 Billion by the end of the analysis period. Growth in the Non-Stimulant Drugs segment is estimated at 10.1% CAGR over the analysis period.

The U.S. Market is Estimated at US$9.2 Billion While China is Forecast to Grow at 7.1% CAGR

The Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics market in the U.S. is estimated at US$9.2 Billion in the year 2023. China, the world's second largest economy, is forecast to reach a projected market size of US$9.0 Billion by the year 2030 trailing a CAGR of 7.1% over the analysis period 2023-2030. Among the other noteworthy geographic markets are Japan and Canada, each forecast to grow at a CAGR of 6.7% and 6.3% respectively over the analysis period. Within Europe, Germany is forecast to grow at approximately 5.9% CAGR.

Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Key Trends and Drivers

Attention Deficit Hyperactivity Disorder (ADHD) is a neurodevelopmental disorder characterized by persistent patterns of inattention, hyperactivity, and impulsivity that interfere with functioning or development. ADHD typically presents in childhood and can continue into adulthood, affecting various aspects of life including academic performance, work, and social interactions. The disorder is commonly diagnosed based on behavioral symptoms, and treatment often involves a combination of behavioral therapies, educational interventions, and pharmacological treatments. Pharmacological therapies are a cornerstone of ADHD management, providing significant symptomatic relief. These treatments are broadly classified into stimulant and non-stimulant medications. Stimulants such as methylphenidate and amphetamines are the most commonly prescribed and are known for their efficacy in increasing attention and reducing hyperactive and impulsive behaviors. Non-stimulant medications, including atomoxetine and certain antidepressants, offer alternatives for patients who do not respond well to stimulants or who experience adverse effects.

The ADHD therapeutics market has evolved significantly over the past few decades, driven by a growing understanding of the disorder and advancements in pharmacology. The development of extended-release formulations has revolutionized ADHD treatment, offering once-daily dosing that improves adherence and provides consistent symptom control throughout the day. Additionally, the introduction of new non-stimulant medications has expanded treatment options, catering to patients with diverse needs and preferences. Pharmaceutical companies are actively engaged in research to develop novel therapeutics that target different pathways involved in ADHD. This includes exploring the role of neurotransmitters other than dopamine and norepinephrine, which are traditionally targeted by current medications. Furthermore, there is increasing interest in personalized medicine approaches, which aim to tailor treatments based on genetic, environmental, and lifestyle factors to optimize efficacy and minimize side effects.

The growth in the ADHD therapeutics market is driven by several factors. Advances in diagnostic techniques and increasing awareness about ADHD are leading to higher diagnosis rates, thereby expanding the patient pool. The rising prevalence of ADHD, particularly in adults, is also contributing to market growth. Technological advancements in drug delivery systems, such as extended-release formulations and transdermal patches, are enhancing patient adherence and satisfaction. Additionally, the development of digital therapeutics and telemedicine platforms is improving access to ADHD care, especially in remote and underserved areas. The increasing acceptance of mental health issues and reduction in stigma associated with ADHD are encouraging more individuals to seek treatment. Furthermore, ongoing research and development efforts aimed at discovering new pharmacological targets and improving existing therapies are expected to drive the market forward. Pharmaceutical companies are also investing in marketing and educational campaigns to raise awareness about the benefits of treatment and encourage early diagnosis and intervention. These factors collectively ensure the robust growth and continued evolution of the ADHD therapeutics market.

Select Competitors (Total 27 Featured) -

  • Alcobra Ltd.
  • Amarantus Bioscience Holdings, Inc.
  • Curemark, LLC
  • Eli Lilly and Company
  • Intellipharmaceutics International, Inc.
  • Janssen Global Services, LLC
  • Mallinckrodt PLC
  • Mylan NV
  • Neos Therapeutics, Inc.
  • Neurovance, Inc.
  • Noven Pharmaceuticals, Inc.
  • Pfizer Inc.
  • Shire plc
  • Supernus Pharmaceuticals, Inc.
  • Tris Pharma, Inc.

TABLE OF CONTENTS

I. METHODOLOGY

II. EXECUTIVE SUMMARY

  • 1. MARKET OVERVIEW
    • Influencer Market Insights
    • Global Economic Update
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics - Global Key Competitors Percentage Market Share in 2024 (E)
    • Competitive Market Presence - Strong/Active/Niche/Trivial for Players Worldwide in 2024 (E)
  • 2. FOCUS ON SELECT PLAYERS
  • 3. MARKET TRENDS & DRIVERS
    • Advances in Diagnostic Techniques Propel Growth in ADHD Therapeutics Market
    • Increasing Awareness about ADHD Expands Addressable Market Opportunity
    • Rising Prevalence of ADHD in Adults Spurs Demand for Therapeutic Solutions
    • Development of Extended-Release Formulations Enhances Patient Adherence and Satisfaction
    • Technological Innovations in Drug Delivery Systems Strengthen Business Case for ADHD Medications
    • Introduction of Non-Stimulant Medications Generates New Market Opportunities
    • Growing Acceptance of Mental Health Issues Accelerates Demand for ADHD Therapies
    • Expansion of Digital Therapeutics and Telemedicine Platforms Improves Access to ADHD Care
    • Increasing Focus on Comorbid Conditions Expands Therapeutic Options for ADHD Patients
    • Advances in Neuroimaging and Biomarker Research Generate Insights for Innovative Treatments
    • Development of Combination Therapies Enhances Efficacy and Patient Outcomes
    • Expanding Pediatric Population Drives Demand for ADHD Treatments
    • Integration of Behavioral and Pharmacological Therapies Generates Comprehensive Care Solutions
  • 4. GLOBAL MARKET PERSPECTIVE
    • TABLE 1: World Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Analysis of Annual Sales in US$ Million for Years 2014 through 2030
    • TABLE 2: World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 3: World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 4: World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets for Years 2014, 2024 & 2030
    • TABLE 5: World Recent Past, Current & Future Analysis for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 6: World Historic Review for Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 7: World 16-Year Perspective for Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 8: World Recent Past, Current & Future Analysis for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 9: World Historic Review for Non-Stimulant by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 10: World 16-Year Perspective for Non-Stimulant by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 11: World Recent Past, Current & Future Analysis for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 12: World Historic Review for Adult by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 13: World 16-Year Perspective for Adult by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 14: World Recent Past, Current & Future Analysis for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 15: World Historic Review for Children by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 16: World 16-Year Perspective for Children by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 17: World Recent Past, Current & Future Analysis for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 18: World Historic Review for Retail Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 19: World 16-Year Perspective for Retail Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030
    • TABLE 20: World Recent Past, Current & Future Analysis for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 21: World Historic Review for Hospital Pharmacy by Geographic Region - USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 22: World 16-Year Perspective for Hospital Pharmacy by Geographic Region - Percentage Breakdown of Value Sales for USA, Canada, Japan, China, Europe, Asia-Pacific and Rest of World for Years 2014, 2024 & 2030

III. MARKET ANALYSIS

  • UNITED STATES
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United States for 2024 (E)
    • TABLE 23: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 24: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 25: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 26: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 27: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 28: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 29: USA Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 30: USA Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 31: USA 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • CANADA
    • TABLE 32: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 33: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 34: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 35: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 36: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 37: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 38: Canada Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 39: Canada Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 40: Canada 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • JAPAN
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Japan for 2024 (E)
    • TABLE 41: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 42: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 43: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 44: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 45: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 46: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 47: Japan Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 48: Japan Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 49: Japan 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • CHINA
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in China for 2024 (E)
    • TABLE 50: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 51: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 52: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 53: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 54: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 55: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 56: China Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 57: China Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 58: China 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • EUROPE
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Europe for 2024 (E)
    • TABLE 59: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2023 through 2030 and % CAGR
    • TABLE 60: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - France, Germany, Italy, UK and Rest of Europe Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 61: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Geographic Region - Percentage Breakdown of Value Sales for France, Germany, Italy, UK and Rest of Europe Markets for Years 2014, 2024 & 2030
    • TABLE 62: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 63: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 64: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 65: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 66: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 67: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 68: Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 69: Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 70: Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • FRANCE
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in France for 2024 (E)
    • TABLE 71: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 72: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 73: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 74: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 75: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 76: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 77: France Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 78: France Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 79: France 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • GERMANY
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Germany for 2024 (E)
    • TABLE 80: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 81: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 82: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 83: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 84: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 85: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 86: Germany Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 87: Germany Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 88: Germany 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • ITALY
    • TABLE 89: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 90: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 91: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 92: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 93: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 94: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 95: Italy Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 96: Italy Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 97: Italy 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • UNITED KINGDOM
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in the United Kingdom for 2024 (E)
    • TABLE 98: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 99: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 100: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 101: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 102: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 103: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 104: UK Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 105: UK Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 106: UK 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • REST OF EUROPE
    • TABLE 107: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 108: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 109: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 110: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 111: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 112: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 113: Rest of Europe Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 114: Rest of Europe Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 115: Rest of Europe 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • ASIA-PACIFIC
    • Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics Market Presence - Strong/Active/Niche/Trivial - Key Competitors in Asia-Pacific for 2024 (E)
    • TABLE 116: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 117: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 118: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 119: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 120: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 121: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 122: Asia-Pacific Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 123: Asia-Pacific Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 124: Asia-Pacific 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030
  • REST OF WORLD
    • TABLE 125: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 126: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Stimulant and Non-Stimulant Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 127: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Drug Type - Percentage Breakdown of Value Sales for Stimulant and Non-Stimulant for the Years 2014, 2024 & 2030
    • TABLE 128: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 129: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Adult and Children Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 130: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Demography - Percentage Breakdown of Value Sales for Adult and Children for the Years 2014, 2024 & 2030
    • TABLE 131: Rest of World Recent Past, Current & Future Analysis for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy - Independent Analysis of Annual Sales in US$ Million for the Years 2023 through 2030 and % CAGR
    • TABLE 132: Rest of World Historic Review for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Retail Pharmacy and Hospital Pharmacy Markets - Independent Analysis of Annual Sales in US$ Million for Years 2014 through 2022 and % CAGR
    • TABLE 133: Rest of World 16-Year Perspective for Attention Deficit Hyperactivity Disorder (ADHD) Therapeutics by Distribution Channel - Percentage Breakdown of Value Sales for Retail Pharmacy and Hospital Pharmacy for the Years 2014, 2024 & 2030

IV. COMPETITION